Tag: Acetylcholinesterase + butyrylcholinesterase inhibitor

  • Rivastigmine

    Acetylcholinesterase + butyrylcholinesterase inhibitor

    A pseudo-irreversible carbamate dual cholinesterase inhibitor approved for Alzheimer disease and Parkinson disease dementia, available as oral and transdermal formulations.

    Abstract

    Rivastigmine (Exelon; CAS 123441-03-2; molecular formula C14H22N2O2; molecular weight 250.34) is a pseudo-irreversible carbamate cholinesterase inhibitor approved by the FDA in 2000 for mild-to-moderate Alzheimer disease and subsequently expanded to Parkinson disease dementia. The compound is distinctive among the marketed AChE inhibitors in showing dual inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE); BChE may play a more prominent role in advanced Alzheimer disease as AChE expression declines, providing a theoretical advantage for rivastigmine in later disease stages. The pseudo-irreversible mechanism involves carbamoylation of the AChE serine residue, with slow regeneration over hours. Pharmacokinetics: short plasma half-life of the parent compound (1 to 2 hours) but the carbamoylation produces extended pharmacological effect (8 to 10 hours functional duration). Available as oral capsules and a transdermal patch (Exelon Patch); the patch produces smoother plasma exposure with reduced gastrointestinal adverse events.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.